AZURITY PHARMACEUTICALS – AZMIRO™: FDA APPROVAL OF THE FIRST PREFILLED TESTOSTERONE CYPIONATE INJECTION FOR INTRAMUSCULAR USE
On January 29, 2024, the FDA approved AZMIRO™ (testosterone cypionate), the first and only FDA-approved prefilled testosterone cypionate injection developed by Azurity Pharmaceuticals for intramuscular use (https://www.azmiro.com/).
The brand name AZMIRO™, developed in collaboration with Want Branding, underwent a comprehensive risk assessment conducted by Brandsymbol’s Regulatory team. Our evaluation ensured the name met FDA safety and distinctiveness standards.
The approval of AZMIRO™ reflects Brandsymbol’s role as a strategic partner in pharmaceutical branding—helping companies bring essential therapies to market with names that are not only distinctive and defensible, but also regulatory-ready.
Learn more about drug name safety testing and our regulatory division: